Mar. 11, 2025 /Count Me In Communications/ —Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute, is launching a new project focused on translocation renal cell carcinoma (tRCC), a rare and aggressive form of kidney cancer. The effort will engage with tRCC patients, empowering them to share their unique health data with scientists to accelerate research on tRCC.

tRCC is a unique type of kidney cancer caused by specific genetic changes called translocations, where parts of chromosomes swap places or rearrange. While tRCC affects individuals across all age groups, it is most commonly diagnosed in children and young adults. Due to its rarity, research on tRCC has historically been limited, leaving patients and families with few therapeutic options and many unanswered questions.

Read the full article on broadinstitute.org